

Table S1: Laboratory data of hospitalized heart transplant recipients with COVID-19 during follow-up (n=33)

HOSPITALIZED PATIENTS ONLY (n=33)	
Laboratory data (during hospitalization/worst result)	
Lymphocytes count (per mm ³)	376(186-601)
D-dimer (ng/mL)	2146(684-5837)
Urea (mg/dL)	101(59-233)
Creatinine (mg/dL)	2.00(1.63-3.43)
High sensitivity C-reactive protein (mg/dL)	123(72-194)

Continuous values are presented as median (interquartile range) and categorical ones as n and percentages.

Table S2: Clinical and laboratory data and outcomes according to the severity of the disease (n=40) and laboratory data at admission and during hospitalization for hospitalized patients (n=33)

Variables	Mild disease (Score < 5) (n=23)	Severe disease (Score ≥ 5) (n=17)	p
Male gender n(%)	14(60.9)	10(58.8)	0.896
Age n(%)	53(45-58)	54(33-61)	0.945
White n(%)	20(87)	12(70.6)	0.201
Etiology			0.834
Ischemic n(%)	1(4.3)	1(5.9)	
Chagas n(%)	9(39.1)	7(41.2)	
Idiopathic n(%)	1(4.3)	0	
Other n(%)	12(52.2)	9(52.9)	
Hypertension n(%)	9(39.1)	5(29.4)	0.524
Diabetes n(%)	7(30.4)	3(17.6)	0.356
Obesity n(%)	0(0)	2(11.8)	0.091
Chronic Obstructive Pulmonary Disease n(%)	0(0)	2(11.8)	0.091
Chronic renal failure n(%)	6(26.1)	9(52.9)	0.083
Signs or Symptoms			
Fever n(%)	10(43.5)	8(47.1)	0.822
Respiratory n(%)	14(60.9)	12(70.6)	0.524
Dyspnea n(%)	5(21.7)	11(64.7)	0.006
Anosmia n(%)	2(8.7)	0	0.212
Dysgeusia n(%)	5(21.7)	1(5.9)	0.165
Gastrointestinal n(%)	8(34.8)	3(17.6)	0.230
Thrombosis at admission n(%)	1(4.3)	1(5.9)	0.826
Immunosuppressive therapy			
Tacrolimus n(%)	14(60.9)	10(58.8)	0.896
Cyclosporine n(%)	8(34.8)	7(41.2)	0.680
Sodium Mycophenolate n(%)	20(87)	13(76.5)	0.388
Azathioprine n(%)	2(8.7)	2(11.8)	0.749
Sirolimus n(%)	1(4.3)	0	0.384
Steroids n(%)	20(87)	15(88.2)	0.904
Left ventricular dysfunction at admission n(%)	1(4.8)	4(23.5)	0.089
Left ventricular ejection fraction (%)	60(60-64)	60(52-64)	0.383
Systolic blood pressure (mmHg)	127(116-132)	118(105-130)	0.196
Diastolic blood pressure (mmHg)	80(74-90)	77(68-81)	0.151
Heart Rate (bpm)	97(90-106)	94(84-100)	0.331
Laboratory data (admission), [median (IQR)]			
Leucocytes count (per mm ³)	5400(4100-6320)	6270(5235-8650)	0.098
Lymphocytes count (per mm ³)	796(608-1394)	707(366-882)	0.116
D-dimer (ng/mL)	555(371-2093)	612(1327-2114)	0.439
Urea (mg/dL)	56(39-72)	72(60-121)	0.013
Creatinine (mg/dL)	1.4(1.1-1.9)	2.0(1.6-2.5)	0.002
High sensitivity C-reactive protein (mg/L)	42(11-78)	67(44-118)	0.136
Medication during COVID-19			
Immunosuppressive therapy withdrawn n(%)	15(65.2)	16(94.1)	0.030
Intravenous steroid n(%)	11(47.8)	16(94.1)	0.002
Antibiotics use n(%)	18(78.3)	14(82.4)	0.749
Hydroxychloroquine n(%)	1(4.3)	0(0)	0.384
Tocilizumab n(%)	0(0)	0(0)	
Therapeutic Anticoagulation n(%)	4(17.4)	7(41.2)	0.096
Prophylactic Anticoagulation n(%)	9(39.1)	7(41.2)	0.896
Vasoactive drug use			
Inotrope n(%)	0(0)	5(29.4)	0.005
Vasopressor n(%)	0(0)	13(76.5)	<0.001
Mechanical circulatory support n(%)	0(0)	3(17.6)	0.036
Intraaortic balloon pump n(%)	0(0)	3(17.6)	0.036
ECMO n(%)	0(0)	0(0)	
Outcomes			
Intensive care unit hospitalization n(%)	3(13)	14(82.4)	<0.001

Mechanical ventilation n(%)	0(0)	9(52.9)	<0.001
Hemodynamic instability (shock) n(%)	0	11(64.7)	<0.001
Thrombosis n(%)	1(4.3)	4(23.5)	0.070
Acute rejection n(%)	1(4.3)	3(17.6)	0.166
30-day mortality n(%)	0(0)	5(29.4)	0.005
Overall mortality n(%)	0(0)	11(64.7)	<0.001
HOSPITALIZED PATIENTS only (n=33)	Mild disease (Score < 5) (n=16)	Severe disease (Score ≥ 5) (n=17)	p
Time of hospitalization [median (IQR)], days	9(5-14)	35(16-50)	<0.001
Laboratory data (at admission) [median (IQR)]			
Lymphocytes count (per mm ³)	721(589-1088)	707(366-882)	0.465
D-dimer (ng/mL)	858(496-2720)	1328(612-2114)	1.0
Urea (mg/dL)	60(40-81)	72(60-121)	0.094
Creatinine (mg/dL)	1.50(1.09-1.94)	2.02(1.63-2.53)	0.011
High sensitivity C-reactive protein (mg/L)	69(18-111)	68(45-119)	0.581
Laboratory data (during hospitalization - worse level) [median (IQR)]			
Lymphocytes count (per mm ³)	570(387-920)	191(107-375)	<0.001
D-dimer (ng/mL)	1394(578-4126)	3336(1982-12903)	0.074
Urea (mg/dL)	63(48-95)	233(103-295)	<0.001
Creatinine (mg/dL)	1.73(1.18-2.08)	3.29(2.00-4.03)	<0.001
High sensitivity C-reactive protein (mg/L)	78(38-144)	130(105-229)	0.041
Ferritin (ng/mL).	517(266-1070)	1055(429-1860)	0.170

Figure S1: Kaplan Meier overall survival rate curves after COVID-19 for all HT recipient's cohort (panel A) and also according to illness severity (panel B).



